Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative adjuvant radiotherapy or chemoradiotherapy with or without nimotuzumab for locally advanced oral cavity carcinoma
ChiCTR2200067130Phase 4Recruiting
- Sponsor
- Peking University School and Hospital of Stomatology
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nimotuzumab in Oral Mucosal Carcinoma (2 arms), sponsored by Peking University School and Hospital of Stomatology. Primary endpoint: Event-free survival. Started Jan 2023; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2200067130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067130.